Free Newsletter
NIH chief breaks with Bush on stem cell research
The head of the National Institutes of Health has called on the White House to reverse its position limiting federal funding of embryonic stem cell research, calling it a shortsighted approach that has sidelined the NIH in an important field. Up until Elias Zerhouni's (photo) testimony to a Senate committee yesterday, he had been careful not to repudiate President Bush's decision to limit federal funding to a group of stem cell lines that already existed when Bush announced his policy in 2001. For the first few years, Zerhouni told lawmakers, the federal policy was harmless and allowed NIH to create an infrastructure for studies. But since 2004, he said, the U.S. has been falling behind other countries that are now taking the lead in the field.
"It's very clear these cell lines will not be sufficient to do all the research we need to do," Zerhouni told lawmakers. "It is clear today that American science will be better served and the nation will be better served if we let our scientists have access to more cell lines."
- read the UPI report on Zerhouni's testimony
Related Articles:
Stem cell research advances. Report
Stem cell advance runs into conservative roadblock. Report
Stem cell researchers dour after Bush veto. Report
U.S. lawmakers aim for new stem cell law. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




